clonidine has been researched along with Subarachnoid Hemorrhage in 5 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Subarachnoid Hemorrhage: Bleeding into the intracranial or spinal SUBARACHNOID SPACE, most resulting from INTRACRANIAL ANEURYSM rupture. It can occur after traumatic injuries (SUBARACHNOID HEMORRHAGE, TRAUMATIC). Clinical features include HEADACHE; NAUSEA; VOMITING, nuchal rigidity, variable neurological deficits and reduced mental status.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clonidine treatment (continuous i." | 5.31 | Sympathetic nervous activation following subarachnoid hemorrhage: Influence of intravenous clonidine. ( Edén, E; Friberg, P; Lambert, G; Naredi, S; Rydenhag, B, 2002) |
| " The first group was used as control group (Control) (n = 20), in the second group subarachnoid hemorrhage was performed (SAH) (n = 20), in the third group Tizanidine was administered in addition to SAH (SAH + Tizanidine administration) (n = 20)." | 3.70 | The effect of tizanidine on chronic vasospasm in rats. ( Berkman, MK; Berkman, MZ; Erbengi, T; Iplikçioğlu, AC; San, T; Sav, A, 2000) |
| " Pulse rate, blood pressure and dosage of the additional antihypertensive medication as signs of sympathetic disturbance were registered." | 2.67 | Beta-blockade in acute aneurysmal subarachnoid haemorrhage. ( Haass, A; Hamann, G; Schimrigk, K, 1993) |
| "Clonidine is an imidazoline derivative antihypertensive medication that is also used as adjunctive therapy for neuropathic pain disorders via topical administration." | 1.40 | Dermal exposure to a compounded pain cream resulting in severely elevated clonidine concentration. ( Fantz, CR; Gooden, CE; Morgan, BW; Pomerleau, AC, 2014) |
| "Clonidine treatment (continuous i." | 1.31 | Sympathetic nervous activation following subarachnoid hemorrhage: Influence of intravenous clonidine. ( Edén, E; Friberg, P; Lambert, G; Naredi, S; Rydenhag, B, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pomerleau, AC | 1 |
| Gooden, CE | 1 |
| Fantz, CR | 1 |
| Morgan, BW | 1 |
| Treggiari, MM | 1 |
| Romand, JA | 1 |
| Martin, JB | 1 |
| Reverdin, A | 1 |
| Rüfenacht, DA | 1 |
| de Tribolet, N | 1 |
| Hamann, G | 1 |
| Haass, A | 1 |
| Schimrigk, K | 1 |
| Berkman, MZ | 1 |
| Iplikçioğlu, AC | 1 |
| Berkman, MK | 1 |
| Erbengi, T | 1 |
| San, T | 1 |
| Sav, A | 1 |
| Lambert, G | 1 |
| Naredi, S | 1 |
| Edén, E | 1 |
| Rydenhag, B | 1 |
| Friberg, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Cervical Sympathetic Block to Increase Cerebral Blood Flow in Patients With Cerebral Vasospasm Following Aneurysmal Subarachnoid Hemorrhage[NCT05230134] | 10 participants (Anticipated) | Interventional | 2023-07-27 | Enrolling by invitation | |||
| Stellate Ganglion Block for the Treatment of COVID-19-Induced Olfactory Dysfunction: A Prospective Pilot Study[NCT05445921] | Phase 1/Phase 2 | 20 participants (Actual) | Interventional | 2022-09-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Participants will be asked to complete the ODOR, which is a patient-reported outcome measure assessing physical problems, functional limitations, and emotional consequences of olfactory dysfunction.~The ODOR has a minimum score of 0 and a maximum score of 112 with higher scores indicating a greater degree of impairment and limitation. The minimal clinically important difference is a change of 15 points." (NCT05445921)
Timeframe: baseline, 5-10 days post SGB #1, and 1 month
| Intervention | score on a scale (Median) | ||
|---|---|---|---|
| ODOR at Baseline | ODOR at 1 Week | ODOR at 1 Month | |
| Stellate Ganglion Block | 62 | 57 | 50.5 |
"Participants will complete the 40-item scratch and sniff UPSIT and mean change will be assessed.~The UPSIT has a minimum score of 0 and maximum score of 40 with lower scores indicating a greater degree of impairment. An UPSIT score of >33 for men and >34 for women is considered normosmic, and the minimal clinically important difference is a change of 4 points." (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | units on a scale (Median) | ||
|---|---|---|---|
| UPSIT at Baseline | UPSIT at 1 Week | UPSIT at 1 Month | |
| Stellate Ganglion Block | 16.5 | 21 | 22.5 |
Participants will be asked about their change in olfactory dysfunction on a 7-point Likert scale from much better to much worse. (NCT05445921)
Timeframe: 5-10 days post SGB #1 and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-I for Smell Loss at 1 Week71922197 | CGI-I for Smell Loss at 1 Month71922197 | CGI-I for Smell Distortion at 1 Week71922197 | CGI-I for Smell Distortion at 1 Month71922197 | CGI-I for Taste Loss at 1 Week71922197 | CGI-I for Taste Loss at 1 Month71922197 | CGI-I for Taste Distortion at 1 Week71922197 | CGI-I for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||
| About the Same | Slightly Better | Much Better | Moderately Better | |||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 15 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 14 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 13 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||
Participants will be asked about the severity of their olfactory dysfunction (and gustatory dysfunction) on a 5-point Likert scale from no smell loss to severe smell loss. (NCT05445921)
Timeframe: baseline, 5-10 days, and 1 month
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CGI-S for Smell Loss at Baseline71922197 | CGI-S for Smell Loss at 1 Week71922197 | CGI-S for Smell Loss at 1 Month71922197 | CGI-S for Smell Distortion at Baseline71922197 | CGI-S for Smell Distortion at 1 Week71922197 | CGI-S for Smell Distortion at 1 Month71922197 | CGI-S for Taste Loss at Baseline71922197 | CGI-S for Taste Loss at 1 Week71922197 | CGI-S for Taste Loss at 1 Month71922197 | CGI-S for Taste Distortion at Baseline71922197 | CGI-S for Taste Distortion at 1 Week71922197 | CGI-S for Taste Distortion at 1 Month71922197 | |||||||||||||||||||||||||||||||||||||||||||||||||
| No Problem | Very Mild Problem | Mild Problem | Moderate Problem | Severe Problem | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 3 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 8 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 5 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 12 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 4 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 10 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 11 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stellate Ganglion Block | 6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2 trials available for clonidine and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Cervical sympathetic block to reverse delayed ischemic neurological deficits after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anesthetics, Local; Angiography, Digital Subtraction; Autonomic Nerve Block; Brain Ischemia; | 2003 |
Beta-blockade in acute aneurysmal subarachnoid haemorrhage.
Topics: Adult; Aneurysm, Ruptured; Autonomic Nervous System; Clonidine; Dihydralazine; Dose-Response Relatio | 1993 |
3 other studies available for clonidine and Subarachnoid Hemorrhage
| Article | Year |
|---|---|
Dermal exposure to a compounded pain cream resulting in severely elevated clonidine concentration.
Topics: Administration, Cutaneous; Adrenergic alpha-2 Receptor Agonists; Adult; Analgesics; Bradycardia; Clo | 2014 |
The effect of tizanidine on chronic vasospasm in rats.
Topics: Adrenergic alpha-2 Receptor Agonists; Animals; Chronic Disease; Clonidine; Disease Models, Animal; F | 2000 |
Sympathetic nervous activation following subarachnoid hemorrhage: Influence of intravenous clonidine.
Topics: Adrenergic alpha-Agonists; Adult; Clonidine; Female; Hemodynamics; Humans; Infusions, Intravenous; M | 2002 |